Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancerReportar como inadecuado




Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Breast Cancer Research

, 6:R24

First Online: 07 November 2003Received: 21 July 2003Revised: 09 October 2003Accepted: 15 October 2003

Abstract

IntroductionMany laboratories are currently evaluating the usefulness of determination of HER2, p53, and Ki67 proliferation indices using immunohistochemical techniques in cancer. Although the available studies suggest that these factors might indeed be helpful in making treatment decisions in cancer patients, their clinical usefulness is still controversial.

MethodsExpression of HER2, p53, and Ki67 was examined by immunohistochemistry in samples of breast tissue from 506 patients with invasive ductal carcinoma, obtained between 1981 and 1999 median follow up period 82 months, and their significance for prognosis was analyzed.

ResultsOf the 506 carcinoma tissue samples, 20.1%, 29.0%, and 53.6% were positive for HER2 over-expression, p53 protein accumulation, and Ki67 expression, respectively. Over-expression of HER2 significantly reduced disease free P = 0.02 and overall survival P = 0.005. Accumulation of p53 protein significantly decreased disease free P = 0.01 and overall survival P = 0.01. Patients with tumors that were positive for both HER2 and p53 relapsed and died within a significantly shorter period of time after surgery P = 0.0001 and P < 0.0001, respectively. In multivariate analysis, patients with both HER2 and p53 positive tumors had considerably decreased overall survival P = 0.04, as did patients with larger tumor size and positive lymph node status.

ConclusionThe findings of the present study indicate that the coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.

KeywordsHER2 immunohistochemistry invasive ductal carcinoma p53 AbbreviationsCMF = cyclophosphamidemethotrexate, and fluorouracil

ERestrogen receptor.

Electronic supplementary materialThe online version of this article doi:10.1186-bcr738 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Autor: Hiroko Yamashita - Mariko Nishio - Tatsuya Toyama - Hiroshi Sugiura - Zhenhuan Zhang - Shunzo Kobayashi - Hirotaka Iwase

Fuente: https://link.springer.com/







Documentos relacionados